Evidence map›Paper›PMID 42942758›Full record

ReviewPharmaceutics2026

A Biology-Driven Framework for Selecting, Engineering, and Validating Physiologically Relevant Multicellular Tumour Models.

Ying-Ta Wu, Darshan T Govindaraju, Girija M Lakshmikanthacharya, Tzu-Yu Hsu, Chen-Fang Lin, Shashwat Sharma, Anilkumar T Shivanna

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ying-Ta WuMatchCure Inc., 3F., No. 632, Guangfu South Road, Da'an District, Taipei City 10695, Taiwan.ORCID 0000-0003-0156-963X
Darshan T GovindarajuMatchCure Inc., 3F., No. 632, Guangfu South Road, Da'an District, Taipei City 10695, Taiwan.
Girija M LakshmikanthacharyaIndependent Researcher, Zhonghe District, New Taipei City 23561, Taiwan.
Tzu-Yu HsuMatchCure Inc., 3F., No. 632, Guangfu South Road, Da'an District, Taipei City 10695, Taiwan.
Chen-Fang LinMatchCure Inc., 3F., No. 632, Guangfu South Road, Da'an District, Taipei City 10695, Taiwan.
Shashwat SharmaInternational Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.
Anilkumar T ShivannaMatchCure Inc., 3F., No. 632, Guangfu South Road, Da'an District, Taipei City 10695, Taiwan.ORCID 0000-0001-9670-7550

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Physiologically relevant tumour models are increasingly used in cancer research, drug development, and functional precision oncology, yet selection often remains platform-led rather than biology-led. This structured critical narrative review proposes an operational framework linking model selection, engineering, and validation to six interdependent domains: multicellular organization and heterogeneity, extracellular-matrix architecture and mechanics, stromal regulation, vascular and interstitial transport, immune regulation and communication, and metabolic regulation with biochemical gradients. The framework distinguishes mechanism-guided questions, in which a candidate causal mechanism can be prespecified, from discovery-oriented questions, in which the determinant is unknown and candidate functions are tested through nested or factorial configurations before a minimal sufficient explanatory model is defined. Required functions are classified as essential, context-modifying, non-essential, or uncertain, and preservation-oriented, reconstruction-oriented, and hybrid strategies are distinguished from the technological format used to implement them. For pharmaceutical applications, delivered exposure, matrix or device binding, tissue penetration, transport, dosing schedule, and recovery are treated as qualification variables when they can change apparent potency or response. The practical contribution is a traceable biology-to-decision record linking the decision and mechanism status to function selection, model configuration, qualification evidence, complexity-retention rules, and claim boundaries. Model qualification is separated from external association, prospective predictive validity, and clinical utility. Among the representative studies appraised, direct functional and configuration-specific pharmacological evidence was demonstrated more often than interlaboratory transfer, independently validated prospective prediction, or clinical utility. Physiological relevance should therefore be demonstrated through decision-critical function rather than inferred from platform complexity or component count. The proposed decision rules remain unvalidated prospectively and across laboratories.

Indexed as

bioprintingdrug deliverydrug discoveryfunctional precision oncologymulticellular tumour modelspatient-derived modelsphysiologically relevant tumour modelstumour microenvironmenttumour-on-chiptumour organoids

Identifiers

PMID42942758
PMCPMC13708530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.